PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

A Study of Adjuvant Chemoradiotherapy with Tri-weekly Cisplatin for Postoperative High-risk Oral Squamous Cell Carcinoma.

Abstract The aim of this study was to assess the feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer.
PMID
Related Publications

Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.

Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).

Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.

Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.

Authors

Mayor MeshTerms

Chemoradiotherapy, Adjuvant

Keywords
Journal Title the tokai journal of experimental and clinical medicine
Publication Year Start




PMID- 28413867
OWN - NLM
STAT- MEDLINE
DA  - 20170417
DCOM- 20170428
LR  - 20170428
IS  - 2185-2243 (Electronic)
IS  - 0385-0005 (Linking)
VI  - 42
IP  - 1
DP  - 2017 Apr 20
TI  - A Study of Adjuvant Chemoradiotherapy with Tri-weekly Cisplatin for Postoperative
      High-risk Oral Squamous Cell Carcinoma.
PG  - 19-24
AB  - OBJECTIVE: The aim of this study was to assess the feasibility and safety profile
      of concurrent chemoradiotherapy with cisplatin in Japanese patients with
      postoperative high-risk oral cancer. METHODS: Patients with high-risk
      pathological features were selected from patients with oral squamous cell
      carcinoma who underwent surgery at the Department of Oral and Maxillofacial
      Surgery, Tokai University Hospital. Patients were given adjuvant
      chemoradiotherapy with tri-weekly cisplatin (100 mg/m2) (66 Gy/33 Fr), and the
      treatment completion rate was examined. RESULTS: A total of 27 patients were
      enrolled between April 2011 and December 2012, including 19 males and 8 females. 
      The median follow-up period was 36 months, and the protocol completion rate was
      81.5%. Grade 3 or higher adverse events included leukopenia in 16 patients
      (59.3%), anemia in 7 patients (25.9%), mucositis in 2 patients (7.4%), increased 
      creatinine in 1 patient (3.7%), nausea in 4 patients (14.8%), and anorexia in 12 
      patients (44.4%). The 3-year overall survival rate was 66.7%, relapse-free
      survival rate was 63.0%, and locoregional control rate was 77.8%. CONCLUSION: The
      feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in 
      Japanese patients with postoperative high-risk oral cancer were comparable to
      pivotal phase III trials.
FAU - Otsuru, Mitsunobu
AU  - Otsuru M
AD  - Department of Oral and Maxillofacial Surgery, Division of Surgery, Tokai
      University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193,
      Japan. [email protected]
FAU - Ota, Yoshihide
AU  - Ota Y
FAU - Aoki, Takayuki
AU  - Aoki T
FAU - Sasaki, Masashi
AU  - Sasaki M
FAU - Suzuki, Takatugu
AU  - Suzuki T
FAU - Denda, Yuya
AU  - Denda Y
FAU - Takahashi, Miho
AU  - Takahashi M
FAU - Akiba, Takeshi
AU  - Akiba T
FAU - Kaneko, Akihiro
AU  - Kaneko A
LA  - eng
PT  - Journal Article
DEP - 20170420
PL  - Japan
TA  - Tokai J Exp Clin Med
JT  - The Tokai journal of experimental and clinical medicine
JID - 7704186
RN  - 0 (Antineoplastic Agents)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage
MH  - Asian Continental Ancestry Group
MH  - Carcinoma, Squamous Cell/surgery/*therapy
MH  - *Chemoradiotherapy, Adjuvant
MH  - Cisplatin/*administration & dosage
MH  - Drug Administration Schedule
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/surgery/*therapy
MH  - Postoperative Period
MH  - Prognosis
MH  - Radiotherapy Dosage
MH  - Risk
MH  - Safety
EDAT- 2017/04/18 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/04/18 06:00
PHST- 2016/11/08 [received]
PHST- 2016/12/08 [accepted]
PST - epublish
SO  - Tokai J Exp Clin Med. 2017 Apr 20;42(1):19-24.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>